BioAlliance Pharma presents additional US pivotal Phase III results on Loramyc™ (miconazole Lauriad®) at the 47th Annual Meeting of the IDSA

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to
the treatment and supportive care of cancer and AIDS patients, has presented results on miconazole
Lauriad® at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in
Philadelphia (October 29 – November 1st).
The additional results from BioAlliance Pharma’s pivotal Phase III study with miconazole Lauriad®
mucoadhesive buccal tablets (MBT) demonstrated comparable efficacy and safety profile to that of
clotrimazole troches (administered five times per day) for oropharyngeal candidiasis (OPC), in HIVpositive
patients in 40 sites in the United States, Canada and South Africa. The data also
demonstrated a good patient compliance as a result of the added convenience of a once-a-day
dosing.
This presentation was given by Dr Rajesh V. Lalla, oral medicine specialist, from the University of
Connecticut Health Center.
OPC, also known as thrush, is an oral fungal infection most common in individuals with weakened
immune systems – particularly those with HIV/AIDS and those undergoing cancer treatments. OPC is
a disruptive condition that results in lesions and inflammation in the mouth, and includes symptoms
such as soreness, burning and/or altered taste.
About IDSA
The Infectious Diseases Society of America (IDSA) represents physicians, scientists and other health
care professionals who specialize in infectious diseases. IDSA’s purpose is to improve the health of
individuals, communities, and society by promoting excellence in patient care, education, research,
public health, and prevention relating to infectious diseases.

091104EN_ IDSA